DTC
ACRS icon

Deep Track Capital’s Aclaris Therapeutics ACRS Stock Holding History

Deep Track Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35M Buy
+9,345,000
New +$31.5M 0.57% 42
2023
Q2 		– Sell
-1,708,971
Closed -$13.8M – 56
2023
Q1 		$13.8M Buy
+1,708,971
New +$21.7M 0.57% 43

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Deep Track Capital's ACRS Position: Q1 2026 in Review

Deep Track Capital opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 9,345,000 shares worth $35M. The stake represents 0.57% of the portfolio and ranks #42 among its holdings. This is a return to the name: Deep Track Capital previously reported a position in ACRS as recently as Q1 2023.

Deep Track Capital first reported a position in ACRS in Q1 2023 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Deep Track Capital held 9,345,000 shares of Aclaris Therapeutics worth $35M as of Q1 2026.
  • Aclaris Therapeutics was a new Deep Track Capital position in Q1 2026.
  • Aclaris Therapeutics made up 0.57% of Deep Track Capital's portfolio in Q1 2026, its #42 holding.
  • Deep Track Capital first reported a position in Aclaris Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.